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A B S T R A C T
Introduction. This study was conducted to determine how long after inﬂatable penile prosthesis (IPP) surgery
patients attempt sexual intercourse and the frequency of subsequent relations. We also examined survival-related
factors for the AMS 700 CX, Mentor Alpha 1, and Mentor Alpha Narrow Base.
Aims. The aim was to survey men who received IPPs and collect information about their return to sexual function
and frequency of use, and to assess the resilience of their devices.
Methods. Phase I involved retrospective chart review of 1,298 virgin IPP surgeries performed by one surgical team
from January 1992 to December 1998. Phase II included 330 subjects selected by stratiﬁed, systematic, random
sampling from phase I patients. Data were collected by computer-assisted telephone interview, using a 27-question
survey. All patients had been instructed to wait 4 weeks before using the implant and were taught how to inﬂate/
deﬂate their prostheses at the 4-week postsurgical visits.
Main Outcome Measures. The survey examines the length of time after surgery for men to resume sexual function.
In the same study, information was garnered about mechanical durability of the device.
Results. Among phase I subjects, the 5-year survival rate was 83% (N = 1,069) for IPP revision for any reason. Of
the 330 phase II subjects, 248 (75%) were successfully contacted; 199 (80%) responded to the full survey and 49
(20%) responded to selected parts of the survey. Sexual intercourse was resumed postoperatively at 1–4 weeks for
41% (78/190), at 5–6 weeks for 31% (59/190), at 7–8 weeks for 16% (30/190), and at >8 weeks for 12% (23/190) of
the patients. More than 60% of patients reported using their IPP at least once weekly.
Conclusion. The three-piece IPP has excellent 5-year survival rates. Most patients return to sexual activity relatively
quickly, with high frequency of usage of their prostheses. Henry GD, BrinkmanMJ, Mead SF, Delk JR II, Cleves
MA, Jennermann C, Wilson SK, and Kramer AC. A survey of patients with inflatable penile prostheses:
Assessment of timing and frequency of intercourse and analysis of implant durability. J Sex Med 2012;9:
1715–1721.
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Introduction
The purpose of the study was to investigate thetiming and frequency of sexual intercourse
among patients with inﬂatable penile prostheses
(IPPs) postoperatively and to identify factors
related to device survival of three types of
IPPs—AMS 700 CX, Mentor Alpha 1, and
Mentor Alpha Narrow Base (NB). The ﬁrst phase
of the study examined the reasons for revision of
the IPPs, including mechanical reliability, infec-
tion, patient and partner satisfaction, and
iatrogenic/medical factors. The second phase of
the study examined patient satisfaction with eachThere was no funding for this study.
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type of prosthesis, sexual satisfaction of the
partner, and the timing and frequency of sexual
activity after penile prosthesis implantation. The
patient satisfaction aspect of this study has been
previously published in the Journal of Urology as a
Continuing Medical Education article [1].
Although there have been many articles pub-
lished on implant survival, a literature search
yielded a limited number of reports on the timing
and frequency of sexual intercourse among
patients with penile prostheses. The literature is
also limited in level of detail. However, both
timing and frequency of intercourse are necessary
to understand patient satisfaction with treatment
for erectile dysfunction (ED). According to a
survey of female partners of men with ED, women
reported that the frequency of sexual intercourse
after the development of ED was signiﬁcantly less
than before the onset of ED [2]. The limited lit-
erature related to penile prostheses sexual inter-
course frequency data indicates a range from 2 to
13 times each month [3–6]. We report patient and
partner survey results of frequency and timing of
sexual intercourse after IPP implantation.
Aims
A computer-assisted telephone interview of penile
implant patients postoperatively was used to assess
various factors in the form of a 27-question survey.
Among the information received was time to
initial device usage after surgery and subsequent
frequency of use. Longer-term follow-up helped
to identify the durability and 5-year survival of
these devices and predisposing factors in device
longevity.
Methods
Phase I: This phase involved retrospective chart
review of 1,298 virgin (ﬁrst-time placement)
three-piece IPP surgeries completed by the same
surgical team at one hospital between January
1992 and December 1998 (Table 1). Population
demographics and etiology have been previously
reported [1]. The goal of this phase was to measure
implant survival among all of the patients who had
virgin implants during that time period. Revision
could have occurred at any time during the study
period in order to make the IPP satisfactory.
Penile Implant Study Data Abstract Form
This phase included data abstraction on the popu-
lation of 1,298 patients with virgin implants, using
one form per implant, and has been previously
described [7]. The same tool was used to abstract
data on the reasons for the revision: (i) mechanical
reliability; (ii) patient and partner satisfaction; (iii)
infection; and/or (iv) iatrogenic/medical reasons.
Data Analysis
Information collected included type of implant,
implant date, patient birth date, and revision
history, including date and reason for revision.
Data concerning 14 different implant devices were
collected, but only three implant types had sufﬁ-
cient numbers and follow-up time for meaningful
analysis: Mentor Alpha NB, Mentor Alpha 1, and
AMS 700 CX. Data management and analysis
were performed using SPSS statistical software
(SPSS Inc., Chicago, IL, USA). Survival estimates
were calculated using the Kaplan–Meier product
limit method and compared with the log-rank test
for each implant type using Stata statistical soft-
ware (Stata Corporation, College Station, TX,
USA). The Kaplan–Meier method was used to
analyze survival with regard to ﬁve categories: (i)
mechanical reliability; (ii) infection; (iii) patient
and partner satisfaction; (iv) iatrogenic/medical
reasons; and (v) survival for any reason [8].
Phase II: The goal of this phase was to measure
patient satisfaction, frequency, and timing of
sexual intercourse. Subjects included 330 patients
selected by stratiﬁed, systematic, random sampling
by device type from among the pool of 1,298 phase
I patients. Patients who, at the time of data collec-
tion, had a revised or new prosthesis, or who did
not currently have prosthesis, were surveyed
regarding the initial virgin implant received.
Patients had been educated to wait 4 weeks after
surgery before using their implant, and at 4 weeks
the patients were taught how to inﬂate/deﬂate
their penile prostheses.
The testing instrument was a survey developed
through review of pertinent literature [9]. The
ﬁnal survey contained seven sections with a total of
27 questions and has been previously described [1].
Data for part II of the study were collected
through a computer-assisted telephone interview.
Table 1 Virgin implant by type of prostheses
Implant type
Virgin implant
N
Mentor Alpha Narrow Base 101
AMS 700 series 93
Mentor Alpha 1 1,104
Total 1,298
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The interviewer was the PhD dissertation
researcher. Institutional Review Board approval
and informed consent were obtained, and conﬁ-
dentiality was assured for each patient participant.
The patient interview data were entered into a
SPSS survey computerized database (SPSS Inc.). If
the patient did not want to participate in the entire
interview, the questions were prioritized, with
the patient initially being asked to response to the
single question “Are you satisﬁed with the
implant?” Data management and analyses were
performed using SPSS statistical software (SPSS
Inc.). The chi-square statistic was used to test cat-
egorical data. Descriptive statistics (counts and
percentages) were used to describe and summarize
the data reﬂecting patient timing and frequency of
intercourse with the three types of penile implants.
Main Outcome Measures
The primary outcomes analyzed in the different
phases of the study are time until initial device
usage after surgery and longevity of the patients’
devices. Data regarding the time to resumption of
sexual function and the frequency of sexual activity
were evaluated. Factors relating to device usage,
satisfaction, and durability were garnered through
the study and were suitable for reporting.
Results
Phase I: Summarized in Table 2 are the outcomes
for the 1,298 virgin three-piece IPPs, with reasons
for revisions, where applicable. There were no sig-
niﬁcant differences among the three types of pros-
theses in terms of the number of revisions for
patient dissatisfaction, iatrogenic/medical, or
mechanical failure.
As shown in Figure 1, the 3-year Kaplan–Meier
estimates of revision-free survival for any reason
for virgin implants by implant type were 85% for
Mentor Alpha 1, 83.8% for AMS 700 CX, and
80.6% for Mentor Alpha NB. The 5-year Kaplan–
Meier estimates of revision-free survival for any
reason for virgin implants were 81.1% for Mentor
Alpha 1, 80.6% for AMS 700 CX, and could not be
determined for Mentor Alpha NB because these
implants had only been followed for a maximum of
3.15 years, at time of data collection. The survival
experience of the three virgin implant types for
failure for any reason was not signiﬁcantly differ-
ent (log-rank test = 2.86, P = 0.2392).
As shown in Figure 2, the 3-year Kaplan–Meier
estimates of revision-free survival because of infec-
tion, for virgin implants by implant type, were
94.8% for Mentor Alpha 1, 95% for AMS 700 CX,
and 87.3% for Mentor Alpha NB. The 5-year
Kaplan–Meier estimates of revision-free survival
Table 2 Reasons for revision (failure) of implant
Reason for revision N %
Not revised within 5 years 1,069 83
Mechanical 82 6
Patient satisfaction 14 1
Infection 66 5
*Iatrogenic/medical 67 5
Total 1,298 100
*Iatrogenic reasons for implant removal may imply a technical issue upon
device placement that rendered it unusable or unsatisfactory, such as cylinder
crossover or reservoir extrusion. It may also mean that the patient was being
explored for unrelated reasons, and as the device was simply unwanted or
posed a theoretical infection risk, it was removed at the same time electively
at the patients’ request
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Figure 1 Kaplan–Meier estimates of revision-free survival
for any reason for virgin implants by implant type.
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Figure 2 Kaplan–Meier estimates of revision-free survival
for infection for virgin implants by implant type.
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for infection for virgin implants were 94.6% for
Mentor Alpha 1, 95% for AMS 700 CX, and could
not be determined for Mentor Alpha NB. The
survival experience of the three virgin implant
types for failure due to infection was signiﬁcantly
different at the 5% level (log-rank test = 7.72,
P = 0.0211). The difference was due to the higher
infection failure rate of the Mentor Alpha NB
implants.
In Table 2, iatrogenic removal of penile implant
implies that the device was removed concomi-
tantly either during another surgery due to patient
lack of use and request for explant or a technical
issue with the implant such as cylinder crossover or
reservoir extrusion. Whereas a repair may have
been feasible, in some cases explant was done, and
they are reﬂected in this category on the table.
Phase II: A total of 330 patients were randomly
selected to participate in the survey. Of these 330
patients, 39 (12%) were deceased and 43 (13%)
could not be contacted. Of the remaining 248
patients, 199 (80%) responded to the full survey
and 49 (20%) refused to participate in the full
survey but agreed to respond to a selected part of
the survey.
The length of time after surgery before sexual
intercourse was resumed was 1–4 weeks for 41%
(78/190), 5–6 weeks for 31% (59/190), 7–8 weeks
for 16% (30/190), and >8 weeks for 12% (23/190)
of patients. More than 60% of patients used their
IPP for sexual intercourse at least once weekly (see
Table 3).
Discussion
Phase I of the study examined factors related to
prosthesis survival. Phase II of the study examined
resumption of sexual intercourse and frequency of
sexual activity with the prosthesis.
Phase I: This study has reported ﬁndings relative
to the experience of 1,298 patients with IPPs, cat-
egorized by implant type. The IPP has been avail-
able for more than 30 years. Wilson et al. reported
that the early models had leakage rates as high as
70% [10]. The current models are results of mul-
tiple product enhancements and signiﬁcant design
improvements over many years.
While all IPPs were virgin implants, the prac-
tice was a tertiary referral center for IPPs, and
many of the Mentor NB implants were placed into
patients with corporal ﬁbrosis. Corporal ﬁbrosis
cases require lengthier treatment, are more com-
plicated, and result in greater tissue damage,
thereby increasing the mechanical failure and
infection rates in this population of patients. The
Mentor NB would be expected to have higher
baseline infection and revision rates because it was
placed in many cases that were inherently more
complex, given the scarring of the corpora.
In 2000, Carson et al. reported the results of
Kaplan–Meier analysis of 372 patients implanted
with AMS 700 CX penile prosthesis [3]. The
2-year Kaplan–Meier survival rate for freedom
from failure for any reason was 89%. In this study,
the 2-year Kaplan–Meier survival rate for freedom
from failure for any reason for AMS 700 CX was
86%. In the study by Carson et al., the 5-year
Kaplan–Meier survival rate of freedom from
failure for any reason was as 79% as compared
with 83% discovered in this study [3]. The survival
rates of this study and the one from Carson et al.
are similar [3].
The current study found that when infection
was examined as a factor in survivability of
implants, there was a signiﬁcant difference by
implant type (P = 0.0068). The overall infection
rate for all implant types was 66/1,298 (5%). This
low infection rate (5%) is consistent with the rates
found by other investigators of the era. For
example, Carson et al. reported that device infec-
tion developed among 12 of the 372 (3.2%)
patients with AMS 700 CX prostheses [3]. In this
study, infection developed in four of the 93 (4.3%)
patients with AMS 700 Series prostheses. These
implants were placed in a period prior to many of
the recent advances in infection reduction, such as
infection-retardant coating and improved surgical
skin preparations.
Table 3 Frequency of sexual intercourse by type of prosthesis: number (%) of patients with each type of prosthesis
Frequency
Alpha Narrow
Base AMS 700s Alpha 1 Total
Daily 2/18 (11) 0/12 (0) 15/167 (9) 17/197 (9)
Biweekly 2/18 (11) 5/12 (42) 49/167 (29) 56/197 (28)
Weekly 8/18 (45) 2/12 (17) 37/167 (22) 47/197 (24)
Bimonthly 2/18 (11) 1/12 (8) 21/167 (13) 24/197 (12)
Monthly 2/18 (11) 1/12 (8) 11/167 (7) 14/197 (7)
Other 2/18 (11) 3/12 (25) 34/167 (20) 39/197 (20)
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Wilson and Delk reported that the infection
rate was 3% for primary implantations performed
by the same team on 823 patients during a 7-year
period from 1986 to 1993 [11]. The lower infec-
tion rate in the earlier study at the same center, as
compared with this current study, may be due to
the fact that in the pre-Viagra era, IPP patients
were generally healthier than the patients of the
current study who did not respond to Viagra. A
substantial difference in rates was shown in a study
by Jarow, who reported that the infection rate for
the patients who underwent uncomplicated
primary implantation was 2/114 (1.8%) [12]. The
overall infection rate for the Jarow study was
11/167 (7%) [12]. In 1995, Parsons reported that
infected penile prostheses may be the current
major cause of implant failure [13]. This study
showed that the primary reason for implant failure
was mechanical and was done prior to any antibi-
otic coating on the IPP. In summary, there was a
signiﬁcant difference in the survival of virgin
implants due to failure because of infection, but
not for failure for any reason.
Phase II: In the present study, both timing to
sexual intercourse following prosthesis implanta-
tion and frequency of sexual intercourse are
reported. Despite the value of such outcomes, very
few studies evaluating the efﬁcacy of penile pros-
theses in the treatment of ED report these data.
Similar to the present study, Carson et al. utilized
a telephone interview for analysis of postoperative
patient satisfaction in a long-termmulticenter study
of AMS 700 CX [3]. Seventy-nine percent of survey
respondents indicated that they used the device at
least twice monthly. In the present study, we found
that more than 60% of surveyed patients had sexual
intercourse once every week; the remaining indi-
cated that they had sexual intercourse bimonthly
(12%) or monthly (7%). Through a mailed ques-
tionnaire following implantation with Ambicor
(American Medical Systems, Inc., Minnetonka,
MN, USA) in 146 men, Lux et al. report that
among the 101 respondents, 88.9% reported con-
tinued use with an average frequency of coitus of 5.1
times per month, similar to the rate of one time per
week reported in the present study [4]. According to
the study by Lux et al., among men not using the
prosthesis for sexual intercourse, the most com-
monly reported reasons were lack of partner (4%)
and lack of interest in sex (4%) [4]. In this study, 68
of the 199 patients (34%) claimed to not currently
be using the prosthesis regularly for intercourse.
The primary reasons were loss of partner for 21%
(14/68), personal health concerns in 16% (11/68),
partner health concerns in 7% (5/68), and perceived
problems with their prosthesis in 56% (38/68).
Ferguson andCespedes also evaluated reliability
and patient satisfaction in a long-term study featur-
ing theDura-II (TimmMedicalTechnologies, Inc.,
Eden Prairie, MN, USA) penile prosthesis [14].
Over a 4-year period, 94 patients were implanted,
85 of which were available for long-term evalua-
tion. At ﬁnal data analysis, 76% of patients also
reported continued sexual activity [14]. Among the
sexually active, the average frequency of inter-
course during the 3–6months before the ﬁnal ques-
tionnaire was six times per month, similar to the
rates found in both the present study and that of
Lux et al. [4,14]. In an outlying study, Salama evalu-
ated the psychosocial aspects of penile prostheses
among patients and partners receiving semirigid
rods [6]. Average frequency of sexual intercourse
was 13 times per month [6]. Eighty-nine percent of
satisﬁed patients reported increased sexual desire
and improved ability to achieve orgasm [6].
In general, data regarding frequency of inter-
course are scarcely reported; however, data related
to timing to sexual activity are evenmore difﬁcult to
ascertain in the literature. This study found that
after surgery, sexual intercourse was resumed by
41% of patients at 1–4 weeks, 31% at 5–6 weeks,
16%at 7–8weeks, and 12%at greater than 8weeks.
Surprisingly, 41% of patients admitted to using
their IPP before device teaching at the 4-week
postoperative visit. Goldstein et al. similarly
reported timing-speciﬁc data in patients implanted
with Mentor Alpha 1: this retrospective study
found that 25% of patients resumed intercourse at
1–4 weeks after surgery, 35% at 5–6 weeks, 5% at 7
weeks, and 28% at 8 weeks or more [15]. Although
frequency data were not outlined in detail due to
the nature of the questionnaire, the authors do note
that 60% of patients had sexual intercourse more
often after surgery, 28% of patients maintained the
same frequency of intercourse, and 12% had sexual
intercourse less frequently [15]. In comparison, our
study found an average frequency of sexual inter-
course of once per week in more than 60% of
surveyed patients. Timing to sexual intercourse was
6 weeks or less in 72%of patients. This study found
frequency of sexual intercourse to be daily for 9%
(17/197), biweekly for 28% (56/197), weekly for
24% (47/197), bimonthly for 12% (24/197),
monthly for 7% (14/197), and other for 20% (39/
197). The chi-square analysis indicated that fre-
quency of intercourse was independent of
prosthesis type (P = 0.893). Of the patients who
answered the survey question regarding length of
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time with partner, themajority of patients had been
with partner for over 10 years, 138/189 (73%). The
next two most frequently answered categories for
length of time with a partner were 4–5 years,
17/189 (9%), and 2–3 years, 15/189 (8%). There-
fore, IPP patients in long-term stable relationships
appear to beneﬁt greatly from implantation in
terms of satisfaction (as previously reported) and
are open to answering survey questions about their
implants [16]. As previously reported and docu-
mented in many studies, satisfaction remains and
continues to be high among patients who undergo
inﬂatable penile implant surgery [17–20].
Overall, information related to sexual timing
and frequency after implantation of a penile pros-
thesis is infrequent and inconsistent. Limitations
of this study include the following: the respective
nature of the questionnaire; recall bias; surgery
was done by experienced prosthetic urologists;
implant durability may change with improvements
in IPP design and/or surgical techniques; and lack
of standardization in patient questioning and
outcome reporting methods consequently inhibits
a conclusive comparative analysis between studies.
Further understanding of the sexual habits of
couples is emerging as a valuable tool in treating
their overall health and well-being [21,22].
Conclusions
The three-piece IPP has high 5-year survival rates.
Most patients return to sexual activity relatively
quickly, with high frequency of usage of their pros-
theses. Mechanical reliability is high, though
breakage does occur. Satisfaction with the IPP is
highest in select patient populations, such asmen in
stable relationships, and those who set reasonable
expectations. Some men, despite having a func-
tional implant, ultimately do not use their devices.
While the reasons for this vary, someof these causes
are ongoing issues with device understanding and
functionality and loss of sexual partner.
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